Takeda is partnering with BioMed Realty to create a 600,000-sf R&D center in Cambridge. Designed by CBT Architects, the 16-story facility will provide sophisticated lab and office environments for the discovery of next-generation biopharmaceutical therapies and vaccines. Takeda has executed a 15-year lease for all of the research floors in the building, which will feature flexible spaces that maximize in-person interaction and connection under a hybrid working model. Furthering the company’s long-term goal of establishing a unified campus in Kendall Square, the project will enable the relocation of 7,000 employees from six Central Square locations. At the base of the building, 15,000 sf of publicly accessible space will include a 300-seat performing arts venue. Spanning three floors, this vibrant community hub will be operated separately from Takeda’s facilities.
Targeting LEED Gold certification or higher, the sustainably designed structure will advance Takeda’s ambitious environmental goals of achieving net-zero greenhouse gas emissions for scopes 1 and 2 before 2035, and for its entire value chain, including currently estimated scope 3 GHG emissions, before 2040. Groundbreaking is slated for October of 2022 with occupancy expected in 2026.
